ストックスクリーナーアプリを入手
52.96
0.51%
-0.27
前日終値:
$53.23
開ける：
$53.41
24時間の取引高:
8.32M
Relative Volume:
0.47
時価総額：
$179.54B
収益：
$45.45B
当期純損益:
$16.18B
株価収益率:
14.59
EPS:
3.6297
ネットキャッシュフロー:
$8.96B
1週間 パフォーマンス:
-2.59%
1か月 パフォーマンス:
-9.84%
6か月 パフォーマンス:
-15.44%
1年 パフォーマンス:
-53.51%
1日の値動き範囲:
$52.93
$53.55
1週間の範囲:
$52.38
$56.23
52週間の値動き範囲:
$45.05
$114.19
Novo Nordisk Adr Stock (NVO) Company Profile
NVO を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
NVO
Novo Nordisk Adr
|
52.96 | 236.52B | 45.45B | 16.18B | 8.96B | 3.6297 |
|
LLY
Lilly Eli Co
|
825.45 | 736.03B | 53.26B | 13.80B | -50.20M | 15.08 |
|
JNJ
Johnson Johnson
|
190.40 | 463.72B | 92.15B | 25.12B | 18.18B | 10.36 |
|
ABBV
Abbvie Inc
|
227.99 | 403.22B | 58.33B | 3.73B | 18.24B | 2.1013 |
|
NVS
Novartis Ag Adr
|
130.36 | 254.84B | 53.40B | 13.68B | 16.89B | 6.8864 |
|
MRK
Merck Co Inc
|
87.49 | 217.76B | 63.43B | 16.42B | 14.72B | 6.4861 |
Novo Nordisk Adr Stock (NVO) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-10-01 | アップグレード | HSBC Securities | Hold → Buy |
| 2025-09-29 | ダウングレード | Morgan Stanley | Equal-Weight → Underweight |
| 2025-09-17 | アップグレード | Berenberg | Hold → Buy |
| 2025-09-16 | アップグレード | Rothschild & Co Redburn | Neutral → Buy |
| 2025-09-09 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2025-08-13 | アップグレード | BNP Paribas Exane | Underperform → Neutral |
| 2025-08-05 | ダウングレード | UBS | Buy → Neutral |
| 2025-07-31 | ダウングレード | HSBC Securities | Buy → Hold |
| 2025-07-30 | ダウングレード | Barclays | Overweight → Equal Weight |
| 2025-04-17 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2025-03-13 | アップグレード | Kepler | Hold → Buy |
| 2025-03-03 | ダウングレード | Stifel | Buy → Hold |
| 2025-02-12 | 開始されました | Morgan Stanley | Equal-Weight |
| 2025-01-06 | アップグレード | Bernstein | Underperform → Mkt Perform |
| 2024-05-30 | 開始されました | Goldman | Buy |
| 2024-04-12 | 開始されました | BMO Capital Markets | Outperform |
| 2024-01-23 | 開始されました | Morgan Stanley | Overweight |
| 2024-01-16 | 再開されました | UBS | Neutral |
| 2023-12-01 | 開始されました | Cantor Fitzgerald | Overweight |
| 2023-10-02 | 開始されました | Argus | Buy |
| 2023-07-14 | 開始されました | HSBC Securities | Buy |
| 2022-07-15 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-06-28 | ダウングレード | UBS | Neutral → Sell |
| 2022-06-27 | アップグレード | Exane BNP Paribas | Underperform → Neutral |
| 2022-06-07 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-05-31 | アップグレード | Guggenheim | Neutral → Buy |
| 2022-04-25 | アップグレード | Cowen | Market Perform → Outperform |
| 2022-04-12 | アップグレード | Morgan Stanley | Underweight → Equal-Weight |
| 2022-03-16 | アップグレード | Deutsche Bank | Hold → Buy |
| 2022-01-25 | ダウングレード | Liberum | Hold → Sell |
| 2021-12-20 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2021-12-17 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2021-01-20 | ダウングレード | Credit Suisse | Outperform → Neutral |
| 2021-01-15 | 開始されました | Deutsche Bank | Buy |
| 2020-09-29 | 開始されました | Berenberg | Hold |
| 2020-07-06 | ダウングレード | BofA Securities | Buy → Neutral |
| 2020-05-11 | ダウングレード | UBS | Buy → Neutral |
| 2020-05-04 | 開始されました | Cowen | Market Perform |
| 2020-03-16 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2020-01-03 | ダウングレード | Guggenheim | Buy → Neutral |
| 2019-11-18 | アップグレード | Barclays | Equal Weight → Overweight |
| 2019-09-17 | アップグレード | Citigroup | Neutral → Buy |
| 2019-08-30 | ダウングレード | Jefferies | Hold → Underperform |
| 2019-06-20 | ダウングレード | Deutsche Bank | Buy → Hold |
| 2019-06-11 | アップグレード | Barclays | Underweight → Equal Weight |
| 2019-04-29 | アップグレード | Credit Suisse | Neutral → Outperform |
| 2019-01-29 | 開始されました | Exane BNP Paribas | Outperform |
| 2018-12-11 | 再開されました | Jefferies | Hold |
| 2018-10-09 | 開始されました | Guggenheim | Buy |
| 2017-12-29 | アップグレード | JP Morgan | Underweight → Neutral |
| 2017-12-06 | アップグレード | BofA/Merrill | Neutral → Buy |
| 2017-12-01 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2017-09-25 | ダウングレード | Exane BNP Paribas | Outperform → Neutral |
| 2017-09-06 | アップグレード | BofA/Merrill | Underperform → Neutral |
すべてを表示
Novo Nordisk Adr (NVO) 最新ニュース
Eccogene Eyes Hong Kong IPO With Experimental Weight-Loss Drug, AstraZeneca Partnership - Benzinga
Novo Nordisk to Convene Extraordinary General Meeting for Board Election - The Globe and Mail
Novo Nordisk Announces Extraordinary General Meeting for Board Elections - The Globe and Mail
J.P. Morgan Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
What's Driving the Market Sentiment Around Novo Nordisk AS? - Sahm
Eli Lilly, Novo Nordisk, Hims & Hers Health Shares Move Lower After Trump Calls Out 'Fat-Loss Drugs' - Sahm
Omeros Stock Skyrockets After Novo Nordisk Strikes $2.1B Rare Disease Drug Deal - Sahm
ETFs Investing in Novo Nordisk A/S Sponsored ADR Class B Stocks - TradingView
Does Novo Nordisk’s Latest Drug Trial Setback Signal a Chance for Investors in 2025? - Sahm
Deutsche Bank Remains a Buy on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk To Acquire Liver Disease Focused Akero Therapeutics For Around $5 Billion - Sahm
UBS Sticks to Their Hold Rating for Novo Nordisk (0QIU) - The Globe and Mail
BMO Capital Remains a Hold on Novo Nordisk (NVO) - The Globe and Mail
J.P. Morgan Sticks to Their Buy Rating for Novo Nordisk (0QIU) - The Globe and Mail
FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Novo Nordisk - sharewise.com
Deutsche Bank Reaffirms Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk ADR earnings missed, revenue topped estimates By Investing.com - Investing.com South Africa
Novo Nordisk ADR earnings missed, revenue topped estimates - Investing.com India
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Novo Nordisk A/S of Class Action Lawsuit and Upcoming DeadlinesNVO | FinancialContent - FinancialContent
NVO Stock Quote Price and Forecast - CNN
NVO DEADLINE: ROSEN, LEADING INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.
NVO IMPORTANT DEADLINE: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Novo Nordisk A/S Investors with Losses in Excess of $100K to Secure Counsel Before Important September 30 Deadline in Securities Class Action - GlobeNewswire Inc.
Tools to assess Novo Nordisk A s (b Shares) Adrhedged’s risk profileJuly 2025 Setups & Technical Pattern Based Buy Signals - newser.com
J.P. Morgan Keeps Their Buy Rating on Novo Nordisk (0QIU) - The Globe and Mail
Novo Nordisk And Prudential Stand Out In European ADR Gains - Finimize
Hims & Hers, Eli Lilly, Novo Nordisk Face FDA Scrutiny: What It Means For Weight-Loss ETFs - Sahm
Custom strategy builders for tracking Novo Nordisk A s (b Shares) AdrhedgedStock Surge & AI Forecasted Entry/Exit Points - newser.com
Novo Nordisk Adr (NVO) 財務データ
収益
当期純利益
現金流量
EPS
0.39%
0.17%
大文字化:
|
ボリューム (24 時間):